ClinicalTrials.gg
CompletedNCT00042068Updated Nov 1, 2013

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

A Phase 3 interventional study of Meloxicam in Arthritis, Rheumatoid, sponsored by Boehringer Ingelheim. Completed at 153 sites in 14 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-11-01.

Sponsored by Boehringer Ingelheim · Phase 3 and Interventional

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Arthritis, Rheumatoid by Boehringer Ingelheim — none open to participants now, none under way, none of them phase 3. Arthritis, Rheumatoid · Boehringer Ingelheim.

Enrollment
Largest of 12
1,000 · median 169
Started
2002
the only one that year
Phase 3
6 of 19
none open now
Registered
1st of 19
by date

Among the 19 studies in Arthritis, Rheumatoid by Boehringer Ingelheim, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2002, is one of 6 in phase 3, and was the 1st registered.

Arthritis, Rheumatoid

3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 19 studies in Arthritis, Rheumatoid by Boehringer Ingelheim is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Arthritis, Rheumatoid by Boehringer Ingelheim as a file.
02

Study summary

A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

03

Conditions studied

  • Arthritis, Rheumatoid
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age greater than or equal to 18 and less than or equal to 80
  • Diagnosis of Rheumatoid Arthritis for at least six weeks
  • Taking an NSAID
  • If female: using adequate
  • Willingness to stop current NSAID until criteria reached to begin study drug
  • Able to provide written

Exclusion criteria

Exclusion Criteria:

  • Intolerance or to NSAIDs or ingredients of trial drug
  • Pregnancy, lactating
  • Use of drug within 30 days prior to entering the trial
  • History of peptic ulcer or of gastrointestinal hemorrhage except simple hemorrhoidal bleeding
  • History of cerebrovascular or other bleeding disorder
  • Severe hypertension
  • Other disease that might interfere with safety of the patient or evaluation of trial drug (investigator's opinion)
  • RA of functional class IV
  • Synovectomy in any large joint within the past 6 months prior to entering the trial or planned during trial
  • Concomitant therapy with anticoagulant, therapeutic doses of aspirin, phenothiazines, lithium, chronic GI-medication, analgesic drug (except acetaminophen up to 4 grams/day)
  • DMARDs initiated within past three months or dose changed less than two months before entering the trial
  • Therapy with exceeding 10 mg/day prednisone equivalent or change in dose within 1 month before trial
  • Concomitant therapy with ACTH within past month before entering the trial.
  • History of narcotic or alcohol abuse (past 12 months)
  • Abnormal laboratory values
  • Previous participation in the present trial
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
1,000 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Response according to American College of Rheumatology 20% (ACR20) classification

    Time frame: at 12 weeks

Secondary outcomes

  1. Number of painful or tender joints

    Time frame: up to 12 weeks

  2. Number of swollen joints

    Time frame: up to 12 weeks

  3. Patient's global (overall) assessment of disease activity

    Time frame: up to 12 weeks

  4. Investigator's global (overall) assessment of disease activity

    Time frame: up to 12 weeks

  5. Patient's assessment of pain

    Time frame: up to 12 weeks

  6. Patient's assessment of physical function (mHAQ)

    Time frame: up to 12 weeks

  7. C-Reactive Protein (CRP)

    Time frame: up to 12 weeks

  8. Withdrawal due to lack of efficacy

    Time frame: up to 12 weeks

  9. Duration of morning stiffness

    Time frame: up to of 12 weeks

  10. Patient's final global (overall) assessment of efficacy

    Time frame: at end of 12 weeks

  11. Investigator's final global (overall) assessment of efficacy

    Time frame: at end of 12 weeks

  12. Patient status with regard to change in arthritic condition

    Time frame: at end of 12 weeks

  13. Use of rescue medication

    Time frame: up to 12 weeks

  14. Incidence and intensity of adverse events

    Time frame: until 4 weeks post treatment

  15. Patient's final global assessment of tolerability

    Time frame: at end of 12 weeks

  16. Investigator's final global assessment of tolerability

    Time frame: at end of 12 weeks

  17. Withdrawals due to adverse events

    Time frame: at end of 12 weeks

07

Study locations

153 sites
  • Suites 570 (research) & 600 (PI)
    Huntsville, Alabama 35801, United States
  • Suite 200
    Montgomery, Alabama 36106, United States
  • Suite 140
    Anchorage, Alaska 99508, United States
  • #106
    Glendale, Arizona 85308, United States
  • Suite 601
    Phoenix, Arizona 85012, United States
  • Suite 201
    Phoenix, Arizona 85015, United States
  • Boehringer Ingelheim Investigational Site
    Los Angeles, California 90048, United States
  • Boehringer Ingelheim Investigational Site
    Pasadena, California 91105, United States
  • Suite 100
    Rancho Cucamonga, California 91730, United States
  • Boehringer Ingelheim Investigational Site
    Rancho Mirage, California 92270-4469, United States
  • Suite 208
    San Diego, California 92108, United States
  • Suite 202
    San Diego, California 92120, United States
  • Suite 301
    San Leandro, California 94578, United States
  • Suite A
    Santa Maria, California 93454, United States
  • Westlake Medical Research
    Westlake Village, California 91361, United States
  • Suite 200
    Colorado Springs, Colorado 80910, United States
  • Suites 205 & 206
    Danbury, Connecticut 06810, United States
  • Suite 300
    Washington, District of Columbia 20006, United States
  • Boehringer Ingelheim Investigational Site
    Del Ray Beach, Florida 33484, United States
  • Boehringer Ingelheim Investigational Site
    Gainsville, Florida 32607, United States
  • Boehringer Ingelheim Investigational Site
    Jacksonville, Florida 32204, United States
  • Boehringer Ingelheim Investigational Site
    Largo, Florida 33773, United States
  • Suite 202
    Miami, Florida 33173, United States
  • Boehringer Ingelheim Investigational Site
    Ocala, Florida 03474, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Boehringer Ingelheim Investigational Site
    Orlando, Florida 32804, United States
  • Suite 2
    Orlando, Florida 32806, United States
  • Suite 406
    Safety Harbor, Florida 34695, United States
  • Boehringer Ingelheim Investigational Site
    Sarasota, Florida 34239, United States
  • Boehringer Ingelheim Investigational Site
    South Miami, Florida 33143, United States
  • Suite 101
    St. Petersburg, Florida 33710, United States
  • Radiant Research
    Stuart, Florida 34996, United States
  • Suite 203
    Tampa, Florida 33614, United States
  • Boehringer Ingelheim Investigational Site
    Zephyrhills, Florida 33540, United States
  • Boehringer Ingelheim Investigational Site
    Coeur d'Alene, Idaho 83814-2644, United States
  • Suite 202
    Idaho Falls, Idaho 83404, United States
  • Boehringer Ingelheim Investigational Site
    Lake Forest, Illinois 60045, United States
  • Boehringer Ingelheim Investigational Site
    Rockford, Illinois 61103, United States
  • Boehringer Ingelheim Investigational Site
    Springfield, Illinois 62704, United States
  • Boehringer Ingelheim Investigational Site
    Indianapolis, Indiana 46202, United States
  • Attn: Kathy Stoddard, Director
    Wichita, Kansas 67207, United States
  • Suite 306
    Wheaton, Maryland 20902, United States
  • Truesdale Clinic
    Fall River, Massachusetts 02720, United States
  • Suite 202
    Kalamazoo, Michigan 49009, United States
  • Suite 101
    St. Louis, Missouri 63128, United States
  • Suite 240
    St. Louis, Missouri 63141, United States
  • Boehringer Ingelheim Investigational Site
    Lincoln, Nebraska 68506, United States
  • Boehringer Ingelheim Investigational Site
    Reno, Nevada 89502-1196, United States
  • PC, Jackson Commons D-2
    Medford, New Jersey 08055, United States
  • Suite 8
    Mercerville, New Jersey 08619, United States
  • Boehringer Ingelheim Investigational Site
    New York, New York 10021, United States
  • Suite 100
    Charlotte, North Carolina 28210, United States
  • Boehringer Ingelheim Investigational Site
    Columbus, Ohio 43214, United States
  • Boehringer Ingelheim Investigational Site
    Tulsa, Oklahoma 74135, United States
  • Boehringer Ingelheim Investigational Site
    Camp Hill, Pennsylvania 17011, United States
  • Altoona Center for Clinical Research
    Duncansville, Pennsylvania 16635, United States
  • Boehringer Ingelheim Investigational Site
    Erie, Pennsylvania 16508-1256, United States
  • Suite D
    Mechanicsburg, Pennsylvania 17055, United States
  • Suite 331-333
    Johnston, Rhode Island 02919, United States
  • Boehringer Ingelheim Investigational Site
    Columbia, South Carolina 29204, United States
  • Suite H
    North Charleston, South Carolina 29406, United States
  • Boehringer Ingelheim Investigational Site
    Orangeburg, South Carolina 29118, United States
  • Boehringer Ingelheim Investigational Site
    Austin, Texas 78705, United States
  • Boehringer Ingelheim Investigational Site
    Dallas, Texas 75225, United States
  • Radiant Research
    Dallas, Texas 75231, United States
  • Suite 200
    Dallas, Texas 75246-1632, United States
  • Suite 500
    Lubbock, Texas 79410, United States
  • Suites 207
    San Antonio, Texas 78217, United States
  • Suite 2A
    Falls Church, Virginia 22044, United States
  • Boehringer Ingelheim Investigational Site
    Everett, Washington 98201, United States
  • Suite D-3
    Seattle, Washington 98166-2967, United States
  • Boehringer Ingelheim Investigational Site
    Yakima, Washington 98902, United States
  • Boehringer Ingelheim Investigational Site
    Buenos Aires, 1405, Argentina
  • Boehringer Ingelheim Investigational Site
    Buenos Aires, 1427, Argentina
  • Boehringer Ingelheim Investigational Site
    Buenos Aires, 1428, Argentina
  • Boehringer Ingelheim Investigational Site
    Rosario, 2000, Argentina
  • Boehringer Ingelheim Investigational Site
    Cotton Tree, Queensland 4558, Australia
  • Emeritus Research
    Malvern, Victoria 3144, Australia
  • Department of Rheumatology
    Perth, Western Australia 6004, Australia
  • Clinique du Parc Léopold
    Bruxelles, 1040, Belgium
  • Medisch Centrum van Huisartsen
    Leuven, 3000, Belgium
  • Av Anhanguera 6479
    Goiânia GO, 74043-011, Brazil
  • Rua Ramiro Barcelos 2350
    Porto Alegre RS, 90035-003, Brazil
  • Boehringer Ingelheim Investigational Site
    São Paulo - SP, 04040-000, Brazil
  • Clínica de Doenças Parasitárias e Infecciosas-Hospital Dia
    São Paulo - SP, 04230-000, Brazil
  • 230-6091
    Richmond, British Columbia V7C 5L9, Canada
  • Boehringer Ingelheim Investigational Site
    Victoria, British Columbia V8P 5P6, Canada
  • Boehringer Ingelheim Investigational Site
    Corunna, Ontario N0N 1G0, Canada
  • Boehringer Ingelheim Investigational Site
    Fort Erie, Ontario L2A 1Z3, Canada
  • Boehringer Ingelheim Investigational Site
    Hamilton, Ontario L8N 1Y2, Canada
  • Dr. Denis O'Donnell
    Kingston, Ontario K7L 2V6, Canada
  • Trillium Health Centre
    Mississauga, Ontario L5B 4A2, Canada
  • Boehringer Ingelheim Investigational Site
    Ottawa, Ontario K2P 1V3, Canada
  • Boehringer Ingelheim Investigational Site
    Peterborough, Ontario K9J 7H8, Canada
  • Boehringer Ingelheim Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • Boehringer Ingelheim Investigational Site
    Scarborough, Ontario M1B 4Y9, Canada
  • 104-532
    St. Catharines, Ontario L2N 4H4, Canada
  • Boehringer Ingelheim Investigational Site
    Toronto, Ontario M3B 2H9, Canada
  • Boehringer Ingelheim Investigational Site
    Windsor, Ontario N8W 5L7, Canada
  • Boehringer Ingelheim Investigational Site
    Montreal, Quebec H3G 1A4, Canada

Showing the first 100 of 153 sites across 14 countries. Choose a country and city above to see the rest.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002 and a completion of Jul 2003. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2002
First posted
Jul 24, 2002
Start
Jun 2002
Completion
Jul 2003
Last update
Nov 1, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Nov 1, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00042068
First posted
Jul 24, 2002
Start date
Jun 2002
Completion
Jul 2003
Last update
Nov 1, 2013

Study contacts

Boehringer Ingelheim Study Coordinator
study chair · Boehringer Ingelheim Ltd./Bracknell
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Meloxicam

Start the discussion